Skip to content

Evaluating Mobile-based Medication Reconciliation by Patients at Home

Evaluating Mobile-based Medication Reconciliation by Patients at Home: Feasibility, Quality and Time Investments by Pharmacy Technicians

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06040151
Acronym
PILLS@HOME
Enrollment
39
Registered
2023-09-15
Start date
2023-10-31
Completion date
2024-05-31
Last updated
2023-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients

Keywords

Patients with all conditions are eligible

Brief summary

Medication reconciliation (MR) is essential to limit drug-related problems that occur during care transitions in and out of care institutions. Pharmacy-led medication reconciliation has been shown to reduce medication discrepancies, preventable harm and hospital readmissions. However, these consultations are time-consuming. The Erasmus Medical Center is currently developing a mobile-based patient portal. After receiving an invitation to perform medication reconciliation in the app, patients can review their medication and allergies at home. Next, pharmacy technicians manually verify all patient-entered data on completeness and quality. The investigators hypothesize that mobile-based medication reconciliation results in increased patient insight. Yet, it is unknown if mobile-based medication reconciliation is feasible, saves time, and is of high quality. Therefore, the primary study objectives are to assess (1) the feasibility of patients performing medication reconciliation using a mobile-based patient portal, (2) the time investment of pharmacy technicians in mobile-based medication reconciliation (and related costs), in comparison to standard practice, and (3) the quality of patients' pre-verified medication lists. The secondary study objective is to assess patients' and pharmacy technicians' acceptability of performing medication reconciliation using a mobile-based patient portal. This is a prospective quality evaluation study assessing mobile-based medication reconciliation. All adult patients (18 years or older) who are admitted to (a selection of) clinical ward in Erasmus Medical Center and who are asked to complete medication reconciliation are eligible. In the patient app, patients review ('pre-verify') their medications and allergies, after which pharmacy technicians check and manually approve ('verify') all patient-entered data and determine whether a follow-up interview is needed. Feasibility is defined as the successful completion rate of digital medication reconciliation, and the need for additional interviews. Time investment by pharmacy technicians (and related costs) are determined by timing the duration of all patient-bound medication reconciliation-related tasks, both in standard care and when using mobile-based reconciliation. The quality of verification is determined by comparing patients' pre-verified medication list to pharmacy technician-verified lists. Acceptability is defined as the perceived usability of medication reconciliation by patients and by pharmacy technicians.

Interventions

DEVICEDigizorg mobile app (quality evaluation study)

Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.

Sponsors

Erasmus Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* 18 years or older * Planned admission to the clinical ward of participating pilot departments in Erasmus MC

Exclusion criteria

* No potential subject will be excluded from participation in this study.

Design outcomes

Primary

MeasureTime frameDescription
The quality of a patient's pre-verified medication list, compared to the pharmacy technician's verified medication listDuring quality evaluation of the mobile-based medication reconciliation tool, an average of 3 monthsThe number of discrepancies between the patient-reported medication list and the pharmacy-verified medication list (the number of changes made by a pharmacy technician in the MR process)
Feasibility (4/4): how often the helpdesk was contactedDuring quality evaluation of the patient app, an average of 3 monthsThe fraction of all patients who were invited to participate in digital MR who contact the helpdesk
The time investment by pharmacy technicians per patient in the digital MR process, compared to the current situation (in minutes)Before launch of the patient app, during an average of 2 months, and during quality evaluation of the patient app, an average of 3 monthsThe time investment by pharmacy technicians per patient in the new workflow vs. the current situation, in which all patients are invited for a live interview
Feasibility (1/4): completion rate of digital MR by patientsDuring quality evaluation of the patient app, an average of 3 monthsThe fraction of all patients who were invited to participate that participated
Feasibility (2/4): the time it takes patients to perform digital MR (in minutes)During quality evaluation of the patient app, an average of 3 monthsTo assess the ease-of-use of performing medication reconciliation in the patient app
Feasibility (3/4): the need for live, follow-up interviews after performing digital MRDuring quality evaluation of the patient app, an average of 3 monthsThe fraction of all patients who were invited to participate in digital MR who needed a live interview

Secondary

MeasureTime frameDescription
Acceptability (2/2): defined as the perceived usability of mobile-based MR by patients and pharmacy technicians, assessed using short qualitative interviews with both patients and pharmacy techniciansDuring quality evaluation of the mobile-based medication reconciliation tool, an average of 3 monthsTo assess to what extent digital medication reconciliation is accepted by patients and pharmacy technicians
Acceptability (1/2): defined as the perceived usability of mobile-based MR by patients, assessed using short in-app questionnaires (VAS 1-5)During quality evaluation of the mobile-based medication reconciliation tool, an average of 3 monthsTo assess to what extent digital medication reconciliation is accepted by patients

Contacts

Primary ContactMartijn Brands, MD
m.r.brands@erasmusmc.nl0031205665675

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026